Immune characterization of pre-clinical murine models of neuroblastoma
Abstract Immunotherapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic therapies. Accurate and reproducible immune competent preclinical models are key to understanding mechanisms of action, interactions with other therapies and mechanisms...
Enregistré dans:
Auteurs principaux: | Emily R. Webb, Silvia Lanati, Carol Wareham, Alistair Easton, Stuart N. Dunn, Tatyana Inzhelevskaya, Freja M. Sadler, Sonya James, Margaret Ashton-Key, Mark S. Cragg, Stephen A. Beers, Juliet C. Gray |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/1cd179c8bd0e4a0ba1a1db6fa9ea0186 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Neuroblastoma
par: Fuentes,Luis, et autres
Publié: (1976) -
Activation of GABA(A) receptors inhibits T cell proliferation.
par: Emma L Sparrow, et autres
Publié: (2021) -
PARATESTICULAR INVOLVEMENT IN NEUROBLASTOMA
par: Volkan KÖSE, et autres
Publié: (2021) -
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
par: Nan Li, et autres
Publié: (2021) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
par: Maged Zeineldin, et autres
Publié: (2020)